Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PKN605 in Atrial Fibrillation
NCT07217067Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of PKN605 in Atrial fibrillation (AFib), sponsored by Novartis. Started Oct 2025; status: recruiting.
02
Drugs
PKN605
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT07217067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07217067.